Ready-to-use AI-driven applications to discover and evaluate predicted novel indications for existing therapeutics
Novel indications for existing therapeutics
We work closely with many pharmaceutical & biotech companies to accelerate and de-risk their indication selection process. Euretos' computational, AI-driven disease models predict novel disease associations that domain experts can evaluate rapidly using our AI-integrated knowledge base.
Novel indication predictions from AI-driven computational disease models
Data-driven approach that minimises potential literature bias
Empowering domain experts to assess results using the Euretos AI Platform
Ready-to-use AI capabilities with rapid onboarding
Data-driven, novel indication candidates
Euretos computational disease models systematically evaluate gene-disease associations across the whole indication landscape to predict novel indications for a target or therapeutic agent.
We support purchasing via scientist.com and science exchange!
Minimise literature bias in indication discovery
To find truly novel indications, we focus on biomolecular and experimental data. By taking into account the indications associated with a target’s biological interaction networks we find yet unexplored disease associations.
Empower your domain experts to evaluate indication predictions
We provide our client's domain experts access to the Euretos AI Platform to evaluate the predicted indications. Here they can assess key target and disease aspects such as multi-omics interactions, gene expression in tissues, cell types and tumors, pathway interactions, regulatory and signalling responses, gene variants, clinical trials, target tractability and patents.
As our computational disease models and AI-integrated knowledge base are ready-to-use, the onboarding process for new clients is very rapid. In-app tutorials and close support of our translational scientists accelerate the learning curve even further.